A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Ian W. Flinn, Ulrich Jaeger, Nirav N. Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Darlene Lu, Xu Zhu, Boris Engels, Jennifer L Brogdon, Jennifer Mataraza, Jaclyn Davis, Anne Laure Marchal, Luisa Mariconti, Michele Moschetta, Laure Moutouh-de Parseval, Pere Barba, Michael Dickinson
Institutions: Sarah Cannon, Vienna General Hospital, Medical University of Vienna, Medical College of Wisconsin, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Hospital de Sant Pau, University of Kansas Medical Center, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Novartis Institutes for BioMedical Research, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3216856495